(1)

Regulation (EU) 2015/2283 provides that only novel foods authorised and included in the Union list of novel foods may be placed on the market within the Union.

(2)

Pursuant to Article 8 of Regulation (EU) 2015/2283, Commission Implementing Regulation (EU) 2017/2470 (2) has established a Union list of novel foods.

(3)

Commission Implementing Regulation (EU) 2023/52 (3) authorised the placing on the market of ‘3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)’ for use in infant formula, follow-on formula, processed cereal-based foods for infants and young children, and baby foods for infants and young children, as defined under Regulation (EU) No 609/2013 of the European Parliament and of the Council (4), milk based drinks and similar products intended for young children, foods for special medical purposes for infants and young children as defined under Regulation (EU) No 609/2013, foods for special medical purposes as defined under Regulation (EU) No 609/2013, excluding foods for infants and young children, and food supplements as defined in Directive 2002/46/EC of the European Parliament and of the Council (5), for the general population, excluding infants and young children.

(4)

On 25 April 2024, the company Chr. Hansen A/S (‘the applicant’) submitted an application to the Commission in accordance with Article 10(1) of Regulation (EU) 2015/2283 for a change of the conditions of use of the novel food ‘3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)’. The applicant requested to increase the maximum authorised use levels of ‘3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)’ in infant formula, follow-on formula and foods for special medical purposes for infants and young children as defined in Regulation (EU) No 609/2013, from the current levels of 0,9 g/L, 0,9 g/L and 1,2 g/L respectively to 1,75 g/L for all three food categories. The applicant also requested to increase the maximum authorised use level of ‘3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)’ in food supplements as defined in Directive 2002/46/EC intended for the general population, excluding infants and young children, from the currently authorised level of 3,0 g/day to 4,0 g/day.

(5)

In accordance with Article 10(3) of Regulation (EU) 2015/2283, the Commission consulted the European Food Safety Authority (‘the Authority’) on 24 June 2024, requesting it to provide a scientific opinion on the changes of the conditions of use of ‘3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)’ as a novel food.

(6)

On 24 March 2025, the Authority adopted its scientific opinion on the ‘safety of the extension of use of 3-fucosyllactose (3-FL) as a novel food pursuant to Regulation (EU) 2015/2283’ (6) in accordance with Article 11 of Regulation (EU) 2015/2283.

(7)

In its scientific opinion, the Authority concluded that the proposed change is safe under the proposed conditions of use, and therefore it is appropriate to amend the conditions of use of ‘3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)’.

(8)

The information provided by the applicant and the Authority’s opinion give sufficient grounds to establish that the changes to the conditions of use of ‘3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)’ are in accordance with the conditions of Article 12 of Regulation (EU) 2015/2283 and should be approved.

(9)

The Annex to Implementing Regulation (EU) 2017/2470 should therefore be amended accordingly.

(10)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,